Cell therapy, also known as cell transplantation therapy, refers to the infusion of normal or bioengineered human cells into cancer patients to inhibit tumor growth. Cell therapy is not broken down by the body's metabolism, and has fewer side effects than traditional chemotherapy and radiotherapy. It has shown great development potential in the field of cancer treatment. In cellular immunotherapy, glucose metabolism plays an important role in cellular immunotherapy. The generation of highly purified and metabolically adapted chimeric antigen receptor immune cells is a huge challenge for cellular immunotherapy. The precise regulation of metabolic pathways will enhance the effect of immunotherapy. Chimeric antigen receptor T-cell therapy is the only FDA-approved chimeric antigen receptor-based therapy. CD BioGlyco provides solutions for the screening and identification of biomarkers related to glucose metabolism in the development of chimeric antigen receptor T cell therapy, optimization of chimeric antigen receptor T cells, and management of cytokine release syndrome.
Fig. 1 Model of metabolic manipulation of T cells (Marchesi F, et al., 2020)
Chimeric antigen receptor T-cell therapy provides a remarkable distinguishing signal between cancer cells and normal cells and is the most effective target for immune recognition and destruction. Through the MOPCGM platform, we can analyze multiple omics data to find biomarkers for different cancer types that can be used for chimeric antigen receptor T cell therapy.
A large number of studies have found that in the process of cancer progression, abnormal glucose metabolism has an important impact on the immune function of T cells. Chimeric antigen receptor T cells require specific metabolic conditions to maintain proliferation and specific potency. Therefore, we optimize the chimeric antigen receptor T cells by targeting the glucose metabolism pathway and expanding the effective therapeutic range of chimeric antigen receptor T cell therapy in cancer treatment.
The specific services we can provide are as follows, including but not limited to:
Cytokine release syndrome, also known as cytokine storm, is a severe systemic inflammatory response caused by the activation of immune cells and the release of a large number of cytokines. It is also the most common adverse reaction of chimeric antigen receptor T cell therapy. The laboratory detected increased serum levels of cytokines such as interleukin-6 and tumor necrosis factor in patients with cytokine release syndrome. These cytokines also have a role in regulating glucose metabolism, and cytokine release syndrome may also be caused by cytokines. Regulation of tumor cell glucose metabolism affects the effect of chimeric antigen receptor T cell therapy. CD BioGlyco can provide in vitro and in vivo cytokine release syndrome detection services.
The specific services we can provide are as follows, including but not limited to:
CD BioGlyco provides solutions to problems related to glucose metabolism during the development of a one-stop chimeric antigen receptor T cell therapy. Our experienced teams of scientists, researchers, and technicians provide fast turnaround, high-quality services at competitive prices for worldwide customers. Our customers have direct access to our staff and prompt feedback on their inquiries. If you are interested in our services, please contact us for more details.
Reference:
